---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037131"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2026-08-11T20:10:35+00:00"
generated_at: "2026-08-11T20:12:44.737692+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sanara Q2 revenue up 9% to $28.1M; adjusted EBITDA $5.0M; MIMEDX acquisition pending

## Summary
- Q2 net revenue $28.1M (+9% YoY); gross margin 93%; adjusted EBITDA $5.0M vs $4.7M.
- Net loss from continuing ops $0.4M ($0.05/diluted share) vs net income $0.5M ($0.05/share) in Q2 2025.
- H1 2026 revenue $55.9M (+14% YoY); adjusted EBITDA $9.3M vs $7.4M.
- Cash and equivalents $15.4M; long-term debt $46.5M at June 30, 2026 vs $16.6M and $46.0M at Dec 31, 2025.
- Announced transformational acquisition by MIMEDX, expected to combine surgical portfolios; subject to customary closing conditions.

## SEC filing metadata
- accession: 0001493152-26-037131
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2026-08-11T20:10:35+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315226037131/0001493152-26-037131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315226037131/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037131
- JSON: https://secwatch.observer/filing/0001493152-26-037131.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.